This Biotech Company's Lead Candidate Treats Rare Cancers As Well As Covid-19 from ot 2019 Watch Video
Preview(s): Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Your browser does not support playing the video.Please download the video!
⏲ Duration: 10:5 👁 View: 175K times ✓ Published: 01-Jun-2024
Description: Dr. Trieu, CEO of Oncotelic Therapeutics, was recently a guest on Benzinga's All Access.<br/><br/>Oncotelic seeks to improve the outcomes and survival of cancer patients, with a special emphasis on rare pediatric cancers. Its lead asset, OT-101, has a rare pediatric designation for diffuse intrinsic pontine glioma. The company has a host of IPs that are being studied in indications as diverse as leukemia, Parkinson’s Disease and erectile dysfunction.<br/><br/>Mr. Trieu spoke about the nanomedicine platform his company is currently building out.